Abstract TP74: MR-001 Improves Stride Length and Cadence in People With Chronic Stroke Walking Impairment
Kirsten Smayda,Arun Jayaraman,Karen J Nolan,Michael Lewek,Paolo Bonato,Mark Newman,David Putrino,Preeti Raghavan,Ryan Pohlig,Brian Harris,Danielle Parker,Sabrina Taylor,Louis Awad
DOI: https://doi.org/10.1161/str.55.suppl_1.tp74
IF: 10.17
2024-02-01
Stroke
Abstract:Introduction: Chronic stroke walking impairments impact approximately 3.5 million Americans and can lead to decreased quality of life, increased fall risk, and increased comorbidities. Stroke results in changes to spatiotemporal gait characteristics, including cadence, stride length, and speed, which can negatively impact walking stability and increase falls. In a multicenter randomized controlled trial, MR-001 was shown to increase comfortable walking speed more than Active Control (walking without MR-001). The purpose of this investigation is to characterize the spatiotemporal gait changes underlying MR-001's improvement in walking speed. Methods: Participants (n = 34) received the MR-001 (InTandemTM) intervention for 30 minutes, 3 times a week for 5 weeks. MR-001 autonomously delivers an individualized and progressive intervention based on the principles of rhythmic auditory stimulation. The device algorithm uses input from foot-worn sensors to change the auditory stimuli in the form of embedded cues in time-shifted music. This secondary analysis from a larger clinical trial included change in stride length and cadence while walking without auditory stimuli, calculated as the change from before to after the intervention, as well as the relative contribution of changes in stride length and cadence to changes in walking speed. Results: Participants showed a significant increase in both stride length [+8%, Δ 0.06 +/- 0.02 m, p < 0.004] and cadence [+4%, Δ 3.04 +/- 1.32 steps/min, p < 0.028]. The average increase in stride length was 2x the established minimal detectable change of 4%. Changes in stride length and cadence each independently predicted the change in speed [ R 2 = 0.99, F (2,31) = 1132.44, p < 0.001], with the change in stride length being the stronger contributor [stride length: β = .78, p < 0.001, cadence: β = .50, p < 0.001]. Conclusions: Post-stroke reductions in stride length and cadence result in slower walking speed and negatively impact walking stability. In conclusion, results of this secondary analysis show that the previously reported increase in walking speed resulting from MR-001 is influenced by stride length more strongly than cadence for individuals with chronic stroke walking impairment.
peripheral vascular disease,clinical neurology